Methods for the identification, assessment, and treatment of patients with cancer therapy
AssigneeMillennium Pharmaceuticals, Inc.
InventorsBarbara M. Bryant, Andrew I. Damokosh, George Mulligan
Life of this patent
Estimating the term…
Loading patent…
AssigneeMillennium Pharmaceuticals, Inc.
InventorsBarbara M. Bryant, Andrew I. Damokosh, George Mulligan
Estimating the term…
The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
A method for determining a cancer therapy regimen for treating myeloma in a patient comprising:
A method for determining a cancer therapy regimen for treating myeloma in a patient comprising:
Dependencies are inferred from the claim text.